Great Science
Deep Compassion
Real Impact
Leveraging our long-standing neuroscience
expertise to develop medicines that
make a difference.
Featured News
April 01, 2026
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
March 12, 2026
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
Leadership in Sleep Medicine
Hear from our Chief Operating Officer Blair Jackson as he shares his perspective on Alkermes’ recently-completed acquisition of Avadel Pharmaceuticals plc.
Understanding Narcolepsy
Narcolepsy is a rare neurological disorder that is often misunderstood and stigmatized. Our team members describe the physical symptoms that people living with this sleep disorder face, along with the emotional and psychological impact, in a video created to foster understanding.
Notable Recognition
We are honored to be recognized as an employer of choice in the life sciences industry. Visit our Awards & Recognition page to see the latest accolades bestowed on Alkermes by leading news and ranking organizations.
R&D Pipeline
We apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We are currently focused on developing these investigational candidates.
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
-
Sodium oxybate extended-release oral suspension
-
Idiopathic Hypersomnia
Phase 3
A once-nightly formulation of sodium oxybate for extended-release oral suspension is currently being evaluated for use in adults with idiopathic hypersomnia in a phase 3 study, REVITALYZ. For more information about this study, please visit clinicaltrials.gov/study/NCT06525077.
-
-
Olanzapine and samidorphan
-
Schizophrenia and Bipolar I Disorder (Pediatric)
Phase 3
Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study, ENLIGHTEN-Youth. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
-
-
Alixorexton
-
Narcolepsy Type 1
Phase 3
-
Narcolepsy Type 2
Phase 3
-
Idiopathic Hypersomnia
Phase 2
Alixorexton (formerly ALKS 2680) is an investigational, oral orexin 2 receptor agonist in development for the treatment of narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.
Alixorexton is currently being evaluted in the phase 3 Brilliance Studies program in adults with narcolepsy type 1 and narcolepsy type 2, and in Vibrance-3, a phase 2 study in adults with idiopathic hypersomnia. Participants who complete one of the Vibrance or Brilliance studies have the option to continue in a long-term, open-label, safety study evaluating the safety of alixorexton for up to two years.
For more information about enrolling studies, please visit brilliancestudies.com,
vibrancestudies.com (for U.S. audiences only), or clinicaltrials.gov for a list of current studies. -
